Global Multiple Myeloma Drugs Market to Reach US$ 35.5 Billion by 2032, Catalyzed by Rising Incidences of the Disease

September 26, 2022 | Healthcare

IMARC Group’s latest report, titled “Multiple Myeloma Drugs Market Report by Therapy (Targeted Therapy, Biologic Therapy, Chemotherapy, and Others), Drug Type (Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, and Others), End-User (Men, Women), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2024-2032,” finds that the global multiple myeloma drugs market size reached US$ 22.3 Billion in 2023. Multiple myeloma, also known as Kahler’s disease, is cancer that forms in the plasma cell, a type of white blood cell. It is generally caused by specific genetic abnormalities and is one of the most prevalent forms of blood cancer. It has no cure but can be managed efficiently using proper therapeutics. Some commonly used pharmaceutical drugs include chemotherapeutic agents, corticosteroids, and immunomodulatory agents. They promote bone healing, alleviate pain, eliminate myeloma cells, control tumor growth, and prevent hypercalcemia, bone fracture, spinal cord compression, and anemia. In recent years, multiple myeloma drugs have gained immense traction across the healthcare sector as they minimize the need for chemotherapy and aid in improving patients’ longevity and quality of life.

Global Multiple Myeloma Drugs Market Trends:

The rising incidences of multiple myeloma represent the primary factor driving the market growth. In addition, healthcare professionals are prescribing multiple myeloma drugs to modulate the immune system and improve the efficiency of cancer therapeutic procedures, such as radiation therapy, platelet transfusion, and stem cell transplant. Along with this, the growing awareness regarding the benefits and effectiveness of biologic therapy drugs in using the immune system of patients to detect and attack myeloma cells is positively influencing the market growth. Since plasma cancer is prevalent among the elderly, the aging population has strengthened the demand for targeted drugs, including immunomodulation agents and monoclonal antibodies, with less severe side effects, as advanced procedures like stem cell transplants are not suitable for physically weak patients. Furthermore, the leading players are introducing microRNA therapeutics and nanomedicines to facilitate the delivery of macromolecular agents into the bone marrow and trigger antitumor responses. In line with this, the increasing funding for research and development (R&D) projects and clinical trials by governing and non-governing agencies of various countries has catalyzed market growth. Other factors, including the widespread prevalence of blood cancer, developments in healthcare infrastructure, technological advancements, and rising healthcare expenditures, are also creating a favorable market outlook. Looking forward, IMARC Group expects the market value to reach US$ 35.5 Billion by 2032, growing at a CAGR of 5.2% during 2024-2032.

Market Summary:

  • Based on the therapy, the market has been classified into targeted, biologic, chemo, and other therapies.
  • The market has been divided based on the drug type into immunomodulatory drugs, proteasome inhibitors, histone deacetylase inhibitors, monoclonal antibody drugs, steroids, and others.
  • On the basis of the end user, the market has been bifurcated into men and women.
  • The market has been categorized based on the distribution channel into hospital, retail, online and other pharmacies.
  • Region-wise, the market has been segmented into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
  • The competitive landscape of the market has also been analyzed, with some of the key players being Amgen Inc., Bristol Myers Squibb, Daiichi Sankyo Co., Ltd., Sanofi-Aventis Groupe (Genzyme Corporation), Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., PHARMA MAR, S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Therapy, Drug Type, End-User, Distribution Channel, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Amgen Inc., Bristol Myers Squibb, Daiichi Sankyo Co., Ltd., Sanofi-Aventis Groupe (Genzyme Corporation), Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., PHARMA MAR, S.A., Takeda Pharmaceutical Company Limited., and Teva Pharmaceutical Industries Ltd.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Multiple Myeloma Drugs Market to Reach US$ 35.5 Billion by 2032, Catalyzed by Rising Incidences of the Disease
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-714-6104


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More